Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Diabetes Trial Unit (DTU) in the Radcliffe Department of Medicine is managing the UK sites for a global study testing if either chloroquine or hydroxychloroquine can prevent COVID-19 in vital frontline healthcare workers.

None

Laboratory evidence shows that these well-established drugs might be effective in preventing or treating COVID-19 but there is no conclusive proof. Despite the lack of strong evidence these drugs are being widely recommended, and they are being widely used in some countries– so finding out if they can protect against COVID-19 - yes or no - is of tremendous importance.

The COPCOV study is a double-blind, randomised, placebo-controlled trial that will enrol 40,000+ frontline healthcare workers and staff from Europe, Africa, Asia and South America who have close contact with patients with COVID-19 to determine definitively if chloroquine and hydroxychloroquine are effective in preventing COVID-19.

It is led by the University of Oxford and Wellcome-supported Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand. The UK sites for the study are being managed by the the Diabetes Trials Unit, which is part of the Radcliffe Department of Medicine at Oxford University.

Enrolment of the first UK participants in COPCOV is beginning today at the Brighton and Sussex University Hospitals and at the John Radcliffe Hospital in Oxford.

Read the full story on the Centre for Tropical Medicine & Global Health (Nuffield Department of Medicine) website

The story is also featured on the University of Oxford website

Similar stories

Sensory Supermarket event helps businesses make public-facing spaces more inclusive for autistic people

Researchers from the Universities of Oxford and Reading – in collaboration with awareness-raising organisation Sensory Spectacle – are hosting an innovative event called Sensory Supermarket as part of the Sensory Street research project.

Tackling suicide risk in people with mental disorders

Clinical researchers from Oxford University’s Department of Psychiatry and Oxford Health NHS Foundation Trust, together with colleagues from elsewhere, have developed guidance to help clinicians identify and treat patients at risk of suicide.

Environmental impact of 57,000 multi-ingredient processed foods revealed

A study estimating the environmental impact of 57,000 food products in the UK and Ireland has been published by an Oxford-led research team in the journal PNAS.

Oxford spinout MiroBio acquired by Gilead Sciences for $405m

The inflammatory diseases company’s rapid ascent and exit underscores the importance of friendships, partnerships and networks in innovation.

DPAG hosts successful first Science in the Park event

More than 100 children, along with around 50 parents, grandparents and caregivers enjoyed an exciting variety of activities on the theme of ‘How the Body Works’ in University Parks on Tuesday 26 July. This ‘Science in the Park’ event was run by the Department of Physiology, Anatomy & Genetics (DPAG) Outreach and Public Engagement Working Group (OPEWG) and volunteers comprising research scientists, clinical anatomy teaching staff, and graduate and undergraduate students.